Presence of retinopathy and incident kidney and cardiovascular events in type 2 diabetes with normoalbuminuria - A post-hoc analysis of the PRIORITY randomized clinical trial

on the behalf of the PRIORITY Study Group; Viktor Rotbain Curovic; Nete Tofte; Morten Lindhardt; Katarina Adamova; Stephan J L Bakker; Joachim Beige; Joline W.J. Beulens; Andreas L Birkenfeld; Gemma Currie; Christian Delles; Ingo Dimos; Lidmila Francová; Marie Frimodt-Møller; Peter Girman; Rüdiger Göke; Tine W. Hansen; Tereza Havrdova; Adriaan Kooy; Gozewijnw D Laverman; Harald Mischak; Gerjan Navis; Giel Nijpels; Marina Noutsou; Alberto Ortiz; Aneliya Parvanova; Frederik Persson; John R Petrie; Piero L Ruggenenti; Femke Rutters; Ivan Rychlík; Justyna Siwy; Goce Spasovski; Marijn Speeckaert; Matias Trillini; Petra Zürbig; Heiko von der Leyen; Peter Rossing

doi:10.1016/j.jdiacomp.2023.108433

Presence of retinopathy and incident kidney and cardiovascular events in type 2 diabetes with normoalbuminuria - A post-hoc analysis of the PRIORITY randomized clinical trial

on the behalf of the PRIORITY Study Group
, Viktor Rotbain Curovic^*
, Nete Tofte
, Morten Lindhardt
, Katarina Adamova
, Stephan J L Bakker
, Joachim Beige
, Joline W.J. Beulens
, Andreas L Birkenfeld
, Gemma Currie
, Christian Delles
, Ingo Dimos
, Lidmila Francová
, Marie Frimodt-Møller
, Peter Girman
, Rüdiger Göke
, Tine W. Hansen
, Tereza Havrdova
, Adriaan Kooy
, Gozewijnw D Laverman

Harald Mischak, Gerjan Navis, Giel Nijpels, Marina Noutsou, Alberto Ortiz, Aneliya Parvanova, Frederik Persson, John R Petrie, Piero L Ruggenenti, Femke Rutters, Ivan Rychlík, Justyna Siwy, Goce Spasovski, Marijn Speeckaert, Matias Trillini, Petra Zürbig, Heiko von der Leyen, Peter Rossing

^*Corresponding author af dette arbejde

Medicin 1

Publikation: Bidrag til tidsskrift › Artikel › Forskning › peer review

Abstract

AIMS: Baseline diabetic retinopathy (DR) and risk of development of microalbuminuria, kidney function decline, and cardiovascular events (CVEs) in type 2 diabetes.

METHODS: Post-hoc analysis of the PRIORITY study including 1758 persons with type 2 diabetes and normoalbuminuria followed for a median of 2.5 (IQR: 2.0-3.0) years. DR diagnosis included non-proliferative and proliferative abnormalities, macular oedema, or prior laser treatment. Cox models were fitted to investigate baseline DR presence with development of persistent microalbuminuria (urinary albumin-creatinine ratio > 30 mg/g); chronic kidney disease (CKD) G3 (eGFR <60 ml/min/1.73m2); and CVE. Models were adjusted for relevant risk factors.

RESULTS: At baseline, 304 (17.3 %) had DR. Compared to persons without DR, they were older (mean ± SD: 62.7 ± 7.7 vs 61.4 ± 8.3 years, p = 0.019), had longer diabetes duration (17.9 ± 8.4 vs. 10.6 ± 7.0 years, p < 0.001), and higher HbA1c (62 ± 13 vs. 56 ± 12 mmol/mol, p < 0.001). The adjusted hazard ratios of DR at baseline for development of microalbuminuria (n = 197), CKD (n = 166), and CVE (n = 64) were: 1.50 (95%CI: 1.07, 2.11), 0.87 (95%CI: 0.56, 1.34), and 2.61 (95%CI: 1.44, 4.72), compared to without DR.

CONCLUSIONS: Presence of DR in normoalbuminuric type 2 diabetes was associated with an increased risk of developing microalbuminuria and CVE, but not with kidney function decline.

Originalsprog	Engelsk
Artikelnummer	108433
Tidsskrift	Journal of Diabetes and Its Complications
Vol/bind	37
Udgave nummer	4
Tidlig onlinedato	18 feb. 2023
DOI	https://doi.org/10.1016/j.jdiacomp.2023.108433
Status	Udgivet - apr. 2023

Adgang til dokumentet

10.1016/j.jdiacomp.2023.108433

Citationsformater

on the behalf of the PRIORITY Study Group, Rotbain Curovic, V., Tofte, N., Lindhardt, M., Adamova, K., Bakker, S. J. L., Beige, J., Beulens, J. W. J., Birkenfeld, A. L., Currie, G., Delles, C., Dimos, I., Francová, L., Frimodt-Møller, M., Girman, P., Göke, R., Hansen, T. W., Havrdova, T., Kooy, A., ... Rossing, P. (2023). Presence of retinopathy and incident kidney and cardiovascular events in type 2 diabetes with normoalbuminuria - A post-hoc analysis of the PRIORITY randomized clinical trial. Journal of Diabetes and Its Complications, 37(4), Artikel 108433. https://doi.org/10.1016/j.jdiacomp.2023.108433

@article{534d6f82f03b4323b56a23737fe6240b,

title = "Presence of retinopathy and incident kidney and cardiovascular events in type 2 diabetes with normoalbuminuria - A post-hoc analysis of the PRIORITY randomized clinical trial",

abstract = "AIMS: Baseline diabetic retinopathy (DR) and risk of development of microalbuminuria, kidney function decline, and cardiovascular events (CVEs) in type 2 diabetes.METHODS: Post-hoc analysis of the PRIORITY study including 1758 persons with type 2 diabetes and normoalbuminuria followed for a median of 2.5 (IQR: 2.0-3.0) years. DR diagnosis included non-proliferative and proliferative abnormalities, macular oedema, or prior laser treatment. Cox models were fitted to investigate baseline DR presence with development of persistent microalbuminuria (urinary albumin-creatinine ratio > 30 mg/g); chronic kidney disease (CKD) G3 (eGFR <60 ml/min/1.73m2); and CVE. Models were adjusted for relevant risk factors.RESULTS: At baseline, 304 (17.3 \%) had DR. Compared to persons without DR, they were older (mean ± SD: 62.7 ± 7.7 vs 61.4 ± 8.3 years, p = 0.019), had longer diabetes duration (17.9 ± 8.4 vs. 10.6 ± 7.0 years, p < 0.001), and higher HbA1c (62 ± 13 vs. 56 ± 12 mmol/mol, p < 0.001). The adjusted hazard ratios of DR at baseline for development of microalbuminuria (n = 197), CKD (n = 166), and CVE (n = 64) were: 1.50 (95\%CI: 1.07, 2.11), 0.87 (95\%CI: 0.56, 1.34), and 2.61 (95\%CI: 1.44, 4.72), compared to without DR.CONCLUSIONS: Presence of DR in normoalbuminuric type 2 diabetes was associated with an increased risk of developing microalbuminuria and CVE, but not with kidney function decline.",

author = "\{on the behalf of the PRIORITY Study Group\} and \{Rotbain Curovic\}, Viktor and Nete Tofte and Morten Lindhardt and Katarina Adamova and Bakker, \{Stephan J L\} and Joachim Beige and Beulens, \{Joline W.J.\} and Birkenfeld, \{Andreas L\} and Gemma Currie and Christian Delles and Ingo Dimos and Lidmila Francov{\'a} and Marie Frimodt-M{\o}ller and Peter Girman and R{\"u}diger G{\"o}ke and Hansen, \{Tine W.\} and Tereza Havrdova and Adriaan Kooy and Laverman, \{Gozewijnw D\} and Harald Mischak and Gerjan Navis and Giel Nijpels and Marina Noutsou and Alberto Ortiz and Aneliya Parvanova and Frederik Persson and Petrie, \{John R\} and Ruggenenti, \{Piero L\} and Femke Rutters and Ivan Rychl{\'i}k and Justyna Siwy and Goce Spasovski and Marijn Speeckaert and Matias Trillini and Petra Z{\"u}rbig and \{von der Leyen\}, Heiko and Peter Rossing",

year = "2023",

month = apr,

doi = "10.1016/j.jdiacomp.2023.108433",

language = "English",

volume = "37",

journal = "Journal of Diabetes and Its Complications",

issn = "1056-8727",

publisher = "Elsevier",

number = "4",

}

on the behalf of the PRIORITY Study Group, Rotbain Curovic, V, Tofte, N, Lindhardt, M, Adamova, K, Bakker, SJL, Beige, J, Beulens, JWJ, Birkenfeld, AL, Currie, G, Delles, C, Dimos, I, Francová, L, Frimodt-Møller, M, Girman, P, Göke, R, Hansen, TW, Havrdova, T, Kooy, A, Laverman, GD, Mischak, H, Navis, G, Nijpels, G, Noutsou, M, Ortiz, A, Parvanova, A, Persson, F, Petrie, JR, Ruggenenti, PL, Rutters, F, Rychlík, I, Siwy, J, Spasovski, G, Speeckaert, M, Trillini, M, Zürbig, P, von der Leyen, H & Rossing, P 2023, 'Presence of retinopathy and incident kidney and cardiovascular events in type 2 diabetes with normoalbuminuria - A post-hoc analysis of the PRIORITY randomized clinical trial', Journal of Diabetes and Its Complications, bind 37, nr. 4, 108433. https://doi.org/10.1016/j.jdiacomp.2023.108433

Presence of retinopathy and incident kidney and cardiovascular events in type 2 diabetes with normoalbuminuria - A post-hoc analysis of the PRIORITY randomized clinical trial. / on the behalf of the PRIORITY Study Group; Rotbain Curovic, Viktor; Tofte, Nete et al.
I: Journal of Diabetes and Its Complications, Bind 37, Nr. 4, 108433, 04.2023.

Publikation: Bidrag til tidsskrift › Artikel › Forskning › peer review

TY - JOUR

T1 - Presence of retinopathy and incident kidney and cardiovascular events in type 2 diabetes with normoalbuminuria - A post-hoc analysis of the PRIORITY randomized clinical trial

AU - on the behalf of the PRIORITY Study Group

AU - Rotbain Curovic, Viktor

AU - Tofte, Nete

AU - Lindhardt, Morten

AU - Adamova, Katarina

AU - Bakker, Stephan J L

AU - Beige, Joachim

AU - Beulens, Joline W.J.

AU - Birkenfeld, Andreas L

AU - Currie, Gemma

AU - Delles, Christian

AU - Dimos, Ingo

AU - Francová, Lidmila

AU - Frimodt-Møller, Marie

AU - Girman, Peter

AU - Göke, Rüdiger

AU - Hansen, Tine W.

AU - Havrdova, Tereza

AU - Kooy, Adriaan

AU - Laverman, Gozewijnw D

AU - Mischak, Harald

AU - Navis, Gerjan

AU - Nijpels, Giel

AU - Noutsou, Marina

AU - Ortiz, Alberto

AU - Parvanova, Aneliya

AU - Persson, Frederik

AU - Petrie, John R

AU - Ruggenenti, Piero L

AU - Rutters, Femke

AU - Rychlík, Ivan

AU - Siwy, Justyna

AU - Spasovski, Goce

AU - Speeckaert, Marijn

AU - Trillini, Matias

AU - Zürbig, Petra

AU - von der Leyen, Heiko

AU - Rossing, Peter

PY - 2023/4

Y1 - 2023/4

N2 - AIMS: Baseline diabetic retinopathy (DR) and risk of development of microalbuminuria, kidney function decline, and cardiovascular events (CVEs) in type 2 diabetes.METHODS: Post-hoc analysis of the PRIORITY study including 1758 persons with type 2 diabetes and normoalbuminuria followed for a median of 2.5 (IQR: 2.0-3.0) years. DR diagnosis included non-proliferative and proliferative abnormalities, macular oedema, or prior laser treatment. Cox models were fitted to investigate baseline DR presence with development of persistent microalbuminuria (urinary albumin-creatinine ratio > 30 mg/g); chronic kidney disease (CKD) G3 (eGFR <60 ml/min/1.73m2); and CVE. Models were adjusted for relevant risk factors.RESULTS: At baseline, 304 (17.3 %) had DR. Compared to persons without DR, they were older (mean ± SD: 62.7 ± 7.7 vs 61.4 ± 8.3 years, p = 0.019), had longer diabetes duration (17.9 ± 8.4 vs. 10.6 ± 7.0 years, p < 0.001), and higher HbA1c (62 ± 13 vs. 56 ± 12 mmol/mol, p < 0.001). The adjusted hazard ratios of DR at baseline for development of microalbuminuria (n = 197), CKD (n = 166), and CVE (n = 64) were: 1.50 (95%CI: 1.07, 2.11), 0.87 (95%CI: 0.56, 1.34), and 2.61 (95%CI: 1.44, 4.72), compared to without DR.CONCLUSIONS: Presence of DR in normoalbuminuric type 2 diabetes was associated with an increased risk of developing microalbuminuria and CVE, but not with kidney function decline.

AB - AIMS: Baseline diabetic retinopathy (DR) and risk of development of microalbuminuria, kidney function decline, and cardiovascular events (CVEs) in type 2 diabetes.METHODS: Post-hoc analysis of the PRIORITY study including 1758 persons with type 2 diabetes and normoalbuminuria followed for a median of 2.5 (IQR: 2.0-3.0) years. DR diagnosis included non-proliferative and proliferative abnormalities, macular oedema, or prior laser treatment. Cox models were fitted to investigate baseline DR presence with development of persistent microalbuminuria (urinary albumin-creatinine ratio > 30 mg/g); chronic kidney disease (CKD) G3 (eGFR <60 ml/min/1.73m2); and CVE. Models were adjusted for relevant risk factors.RESULTS: At baseline, 304 (17.3 %) had DR. Compared to persons without DR, they were older (mean ± SD: 62.7 ± 7.7 vs 61.4 ± 8.3 years, p = 0.019), had longer diabetes duration (17.9 ± 8.4 vs. 10.6 ± 7.0 years, p < 0.001), and higher HbA1c (62 ± 13 vs. 56 ± 12 mmol/mol, p < 0.001). The adjusted hazard ratios of DR at baseline for development of microalbuminuria (n = 197), CKD (n = 166), and CVE (n = 64) were: 1.50 (95%CI: 1.07, 2.11), 0.87 (95%CI: 0.56, 1.34), and 2.61 (95%CI: 1.44, 4.72), compared to without DR.CONCLUSIONS: Presence of DR in normoalbuminuric type 2 diabetes was associated with an increased risk of developing microalbuminuria and CVE, but not with kidney function decline.

U2 - 10.1016/j.jdiacomp.2023.108433

DO - 10.1016/j.jdiacomp.2023.108433

M3 - Article

C2 - 36841085

SN - 1056-8727

VL - 37

JO - Journal of Diabetes and Its Complications

JF - Journal of Diabetes and Its Complications

IS - 4

M1 - 108433

ER -

on the behalf of the PRIORITY Study Group, Rotbain Curovic V, Tofte N, Lindhardt M, Adamova K, Bakker SJL et al. Presence of retinopathy and incident kidney and cardiovascular events in type 2 diabetes with normoalbuminuria - A post-hoc analysis of the PRIORITY randomized clinical trial. Journal of Diabetes and Its Complications. 2023 apr.;37(4):108433. Epub 2023 feb. 18. doi: 10.1016/j.jdiacomp.2023.108433

Presence of retinopathy and incident kidney and cardiovascular events in type 2 diabetes with normoalbuminuria - A post-hoc analysis of the PRIORITY randomized clinical trial

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater